| Issue |
Title |
| Vol 22, No 1 (2020) |
Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer |
|
|
Kolyadina I.V., Danzanova T.Y., Khokhlova S.V., Trofimova O.P., Kovaleva E.V., Rodionov V.V., Poddubnaya I.V. |
| Vol 17, No 1 (2015) |
A population-based portrait of breast cancer in russia: a cancer register-based analysis in russian |
|
|
Poddubnaya I.V., Kolyadina I.V., Kalashnikov N.D., Borisov D.A., Makarova M.V. |
| Vol 22, No 1 (2020) |
The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study |
|
|
Kovalenko E.I., Artamonova E.V., Karabina E.V., Andreiashkina I.I., Prokof’eva E.A., Popova N.O., Gaisina E.A., Evstigneeva I.V., Shaidorov M.V., Zhiliaeva L.A., Ponomarenko D.M., Khasanova A.I., Mukhametshina G.Z., Koziakov A.E., Vorotilina L.V., Povyshev A.I., Simolina E.I., Marfutov V.V., Kozlov D.V., Suslova I.R., Shikina V.E., Karandeeva T.V., Shepel’ A.O., Kramskaia L.V., Oskirko D.A., Frolova O.S. |
| Vol 16, No 3 (2014) |
Avastin in clinical chemotherapy of malignant tumors |
|
|
Gorbunova V.A. |
| Vol 15, No 3 (2013) |
Prognosticheskoe znachenie lokal'nogo i sistemnogo lecheniya pri rake molochnoy zhelezy I stadii |
|
|
Kolyadina I.V., Poddubnaya I.V., Trofimova O.P., Komov D.V., Karseladze A.I., Ermilova V.D., Vishnevskaya Y.V., Frank G.A., Banov S.M. |
| Vol 17, No 1 (2015) |
Immunological heterogeneity of stage I breast cancer:biological, population-based and prognostic value (international cooperation experience) |
|
|
Kolyadina I.V., Poddubnaya I.V., Van de Velde C.J., Kuppen P.J., Frank G.A., Komov D.V., Karseladze A.I., Bastiaannet E., Dekker-Ensink N.G. |
| Vol 20, No 2 (2018) |
The first results of the national programme for the diagnosis and treatment of HER2-positive breast cancer in Turkmenistan |
|
|
Berdimyradova M.B., Khadjiev S.M., Khommadova D.N., Polatova G.O., Kakajanova A.O., Batyrov C.B., Penayev D.N., Agayeva B.G., Annaberdiyeva G.A. |
| Vol 18, No 2 (2016) |
Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype |
|
|
Karabina E.V., Zhukova L.G. |
| Vol 19, No 1 (2017) |
Predictive factors of achievement pathological complete response at neoadjuvant chemotherapy of primary operable breast cancer |
|
|
Pavlikova O.A., Kolyadina I.V., Komov D.V., Vishnevskaya Y.V., Poddubnaya I.V. |
| Vol 15, No 2 (2013) |
Prognostic value of p53 expression in patients with stage I breast cancer |
|
|
Kolyadina I.V., Poddubnaya I.V., Van de Velde C.J., Kuppen P.J., Liefers G.J., Dekker-Ensink N.G., Bastiaannet E., Van As-Sajet A., Prinse B., Engels C., Van Vlierberghe R., Komov D.V., Karseladze A.I., Ermilova V.D., Vishnevskaya Y.V., Frank G.A., Banov S.M. |
| Vol 20, No 3 (2018) |
The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer |
|
|
Kolyadina I.V., Poddubnaya I.V. |
| Vol 21, No 3 (2019) |
The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer |
|
|
Gordeeva O.O., Kolyadina I.V., Zhukova L.G., Gan'shina I.P., Komov D.V., Meshcheriakov A.A. |
| Vol 18, No 1 (2016) |
Rare morphological forms of breast cancer: features of surgical approach |
|
|
Vysotskaya I.V., Letyagin V.P., Kolyadina I.V., Martynova G.V. |
| Vol 11, No 4 (2009) |
Denosumab (AMG-162) v profilaktike osteoporoza, vyzvannogo priemom ingibitorov aromatazy u bol'nykh rakom molochnoy zhelezy v ad\"yuvantnoy terapii i u bol'nykh rakom predstatel'noy zhelezy pri polnoy androgennoy blokade |
|
|
Lichinitser M.R., Semenov N.N. |
| Vol 17, No 1 (2015) |
The use of combined plastic interventions in the reconstruction of post-operative soft tissue defects of the chest wall in the surgical treatment of locally advanced breast cancer |
|
|
Vashenko L.N., Daschkova I.R., Bakulina S.M., Andreyko E.A. |
| Vol 21, No 1 (2019) |
The potential use of oncolytic viruses in breast cancer: historical aspects and future prospects (literature review) |
|
|
Morozov D.A., Kolyadina I.V., Poddubnaya I.V., Chumakov P.M., Ilinskaya G.V., Bokhian V.Y., Sopova M.I. |
| Vol 19, No 2 (2017) |
PARP inhibitors in female reproductive system cancers |
|
|
Pokataev I.A., Tyulyandin S.A. |
| Vol 8, No 1 (2006) |
Keliks (pegilirovannyy liposomal'nyy doksorubitsin) v programmnoy terapii 2-y linii metastaticheskogo raka molochnoy zhelezy |
|
| Vol 20, No 2 (2018) |
The post-mastectomy syndrome: the secondary lympedema after the combined treatment of breast cancer (the literature review and own results) |
|
|
Stepanova A.M., Merzlyakova A.M., Khulamhanova M.M., Trofimova O.P. |
| Vol 9, No 3 (2007) |
Fulvestrant v sovremennoy terapii rasprostranennogo raka molochnoy zhelezy: farmakoekonomicheskoe obosnovanie |
|
|
Komarova V.P., Komarova L.E., Poddubnaya I.V. |
| Vol 19, No 3 (2017) |
Dynamics of circulating tumor cells during neoadjuvant chemotherapy in patients with locally-advanced breast cancer |
|
|
Nenakhova Y.N., Lyadov V.K., Poddubnaya I.V. |
| Vol 17, No 4 (2015) |
Neoadjuvant systemic therapy of HER2-positive breast cancer |
|
|
Frolova M.A. |
| Vol 16, No 3 (2014) |
Experience of eribulin application in previously treated patients with metastatic or locally recurrent breast cancer under the clinical trial |
|
|
Ahmetzanov F.S., Ahmetzanova F.F. |
| Vol 11, No 1 (2009) |
Problemy endokrinoterapii raka molochnoy zhelezy u muzhchin |
|
|
Borisova E.I., Voronina I.Y., Gutorov S.L. |
| Vol 18, No 3 (2016) |
The results of epidemiological screening program of HER2 status in patients with breast cancer in the federal districts of the Russian Federation in 2015 |
|
|
Poddubnaya I.V., Frank G.A., Yagudina R.I., Koroleva N.I., Zavalishina L.E. |
| Vol 8, No 1 (2006) |
Opyt primeneniya Taksotera v kombinatsii s doksorubitsinom v kachestve khimioterapii 1-y linii u bol'nykh metastaticheskim rakom molochnoy zhelezy |
|
|
Samoylenko V.M., Gorbunova V.A., Koshelev M.N., Yurashko K.V. |
| Vol 7, No 1 (2005) |
Faktory prognoza pri rake molochnoy zhelezy |
|
|
Bozhok A.A., Semiglazov V.F., Semiglazov V.V., Arzumanov A.S., Kletsel' A.E. |
| Vol 16, No 4 (2014) |
Male breast cancer: review of the literature |
|
|
Nikolaev K.S., Semiglazov V.F., Semiglazov V.V. |
| Vol 9, No 3 (2007) |
Postmastektomicheskaya limfedema verkhnikh konechnostey: vozmozhnosti konservativnogo lecheniya |
|
|
Myasnikova M.O. |
| Vol 19, No 4 (2017) |
Soft tissue metastases of the gluteal region in HER2+ breast cancer: a clinical case |
|
|
Kolyadina I.V., Ganshina I.P., Zhukova L.G., Abdullaev A.G., Andreeva Y.Y., Danzanova T.Y., Sinyukova G.T., Komov D.V., Kozlov N.A., Filonenko D.A., Gordeeva O.O., Lubennikova E.V. |
| Vol 9, No 1 (2007) |
Antiestrogennaya terapiya pri rake molochnoy zhelezy. Naskol'ko bezopasny ingibitory aromatazy? |
|
|
Ptushkin V.V. |
| Vol 7, No 2 (2005) |
Farmorubitsin v klinicheskoy praktike |
|
|
Gorbunova V.A. |
| Vol 11, No 4 (2009) |
Aromazin v ad\"yuvantnoy terapii raka molochnoy zhelezy |
|
|
Artamonova E.V. |
| Vol 20, No 2 (2018) |
Ribociclib in 1st line HR+ breast cancer treatment |
|
|
Zhukova L.G., Ganshina I.P., Gordeeva O.O., Lubennikova E.V. |
| Vol 9, No 2 (2007) |
Sravnitel'noe issledovanie opredeleniya NER2-statusa raka molochnoy zhelezy metodami immunogistokhimii i in situ gibridizatsii |
|
|
Zavalishina L.E., Andreeva Y.Y., Ryazantseva A.A., Bateva M.V., Frank G.A. |
| Vol 7, No 3 (2005) |
Sovremennye vozmozhnosti lekarstvennoy terapii operabel'nogo raka molochnoy zhelezy (po materialam St. Gallen, 2005) |
|
|
Letyagin V.P., Vysotskaya I.V. |
| Vol 21, No 1 (2019) |
Opportunities of the pharmacogenetic approach to personalized tamoxifen breast cancer therapy: case reports |
|
|
Savelyeva M.I., Dudina I.A., Zaharenkova J.S., Ignatova A.K., Ryzhikova K.A., Sozaeva Z.A., Kudlay D.A., Perfileva O.M., Poddubnaya I.V. |
| Vol 17, No 2 (2015) |
Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy |
|
|
Krivorotko P.V., Burdaeva O.N., Nechaeva M.N., Frolova M.A., Kopp M.V., Abrosimova A.A., Ivanov R.A. |
| Vol 11, No 1 (2009) |
Bevatsizumab (Avastin) v kombinatsii s taksanami v 1-y linii lecheniya HER-2-negativnogo metastaticheskogo raka molochnoy zhelezy(Rezul'taty issledovaniya AVADO) |
|
|
Zhukova L.G. |
| Vol 9, No 1 (2007) |
Immunogistokhimicheskoe opredelenie ekspressii HER2/neu pri rake molochnoy zhelezy (po dannym Smolenskogo oblastnogo onkologicheskogo klinicheskogo dispansera) |
|
|
Shisterova O.A., Golik E.P. |
| Vol 7, No 2 (2005) |
Aromazin (ekzemestan) v neoad\"yuvantnoy i ad\"yuvantnoy gormonoterapii raka molochnoy zhelezy |
|
|
Makarenko N.P. |
| Vol 19, No 2 (2017) |
Perspectives of pharmacogenetics approach to personalized tamoxifen therapy |
|
|
Savelyeva M.I., Ignatova A.K., Panchenko Y.S., Urvantseva I.A., Poddubnaya I.V. |
| Vol 18, No 2 (2016) |
New opportunities to improve of duration and quality of life: eribulin in the treatment of patients with advanced breast cancer |
|
|
Semiglazova T.Y., Klyuge V.A., Semiglazov V.V., Teletaeva G.M., Krivorotko P.V., Dashyan G.A., Paltuev R.M., Tkachenko E.V., Donskikh R.V., Semiglazov V.F. |
| Vol 11, No 4 (2009) |
Press-reliz Na XIII Rossiyskom kongresse onkologov obsudili sostoyanie epidemiologicheskoy programmy skrininga HER2-statusa u zhenshchin, bol'nykh rakom molochnoy zhelezy (RMZh), a takzhe preimushchestvai perspektivy targetnoy terapii preparatami Gertseptin i Avastin |
|
| Vol 20, No 2 (2018) |
Case studies on clinical experience of targeted therapy ribociclib in combination with letrozole in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer |
|
|
Frolova M.A., Kochetkova Y.I., Chubenko V.A., Volkov N.M., Moiseenko F.V., Garmarnik T.V., Ponomarenko D.M., Orlov A.E., Kostalanova Y.V., Makarycheva Y.Y., Nizegorodzeva A.A. |
| Vol 19, No 1 (2017) |
Albumin-bound paclitaxel in the treatment of metastatic breast cancer |
|
|
Artamonova E.V. |
| Vol 9, No 3 (2007) |
Odnomomentnye mastektomii i laparoskopicheskie ovariektomii v lechenii raka molochnoy zhelezy |
|
|
Khvastunov R.A., Kireev A.V., Nikol'skiy I.V., Suvorov V.A. |
| Vol 17, No 2 (2015) |
Stereotactic biopsy of breast lesions under x-ray control |
|
|
Manikhas G.M., Safronova O.B., Khudjakova T.G., Barabanova L.P., Punanova N.J. |
| Vol 16, No 3 (2014) |
Personalized approach to HER2-positive advanced breast cancertherapy |
|
|
Stenina M.B. |
| Vol 8, No 4 (2006) |
Vliyanie rekonstruktivno-plasticheskikh operatsiy na kachestvo zhizni bol'nykh rakom molochnoy zhelezy v otdalennom periode |
|
|
Arslanov K.S., Tkachenko G.A. |
| Vol 19, No 2 (2017) |
Internal mammary nodes metastases for breast cancer: whether the morphological verification is necessary? |
|
|
Trigolosov A.V., Uimanov V.A., Chernikh M.V., Petrovskiy A.V., Nikitina E.A., Nechushkin M.I. |
| Vol 17, No 1 (2015) |
Quality of life is the fundamental criterion of the efficacy of targeted therapy in patients with metastatic Her2-positive breast cancer |
|
|
Semiglazova T.Y., Dashyan G.A., Semiglazov V.V., Zhabina A.S., Osipov M.A., Kotova Z.S., Klimenko V.V., Krivorotko P.V., Semiglazov V.F. |
| Vol 20, No 2 (2018) |
Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved? |
|
|
Zhukova L.G., Ganshina I.P., Khatkova E.I., Tikhomirova T.E., Kondratyeva O.E. |
| Vol 16, No 4 (2014) |
Tumor biology or adjuvant systemic therapy: what determines the risk of recurrence in breast cancer stage I? |
|
|
Kolyadina I.V., Poddubnaya I.V., Trofimova O.P., Frank G.A., Karseladze A.I., Komov D.V. |
| Vol 15, No 4 (2013) |
The main markers of the long-term efficiency of neoadjuvant chemotherapy in breast cancer (review of literature) |
|
|
Semiglazov V.F., Semiglazov V.V., Paltuev P.M., Nikolaev K.S., Dashyan G.A. |
| Vol 9, No 2 (2007) |
Primenenie Zomety na fone endokrinnoy terapii Femaroy u bol'nykh rakom molochnoy zhelezy s metastazami v kosti |
|
|
Konstantinova M.M., Ovchinnikova L.K., Lomakin N.N., Galleev M.G., Neretina E.S., Mukhamedshina G.Z., Mukhametgaleeva F.K. |
| Vol 7, No 3 (2005) |
Aromazin: printsip deystviya |
|
|
Imyanitov E.N. |
| Vol 21, No 1 (2019) |
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia |
|
|
Gorbunova V.A., Kolyadina I.V., Kovalenko E.I., Manziuk L.V., Artamonova E.V., Zhukova L.G., Bolotina L.V., Semiglazova T.I., Manikhas A.G., Raevskaia N.A., Itkin I.M., Filonenko D.V., Zhilyaeva L.A., Gol'dberg V.E., Popova N.O., Ponomarenko D.M., Shikina V.E., Suslova I.R., Romanchuk O.V., Kozlov D.V., Rzaev A.S., Marfutov V.V., Andreiashkina I.I., Vladimirova L.I., Mitashok I.S., Tikhanovskaia N.M., Karabina E.V., Mukhametshina G.Z., Khasanova A.I., Safina S.Z., Shaidorov M.V., Morozov D.A., Prokof'eva E.P., Kramskaia L.V., Karandeeva T.V., Evstigneeva I.V., Ovchinnikova E.G., Klement'eva T.P., Khrupalo O.V., Tiuvinova E.V., Sherstnev V.M., Chernov I.S., Kolokolov D.D., Gaisina E.A., Levchenko N.V., Chubenko V.A., Povyshev A.I., Iudina I.V., Vorotilina L.V., Andreeva T.V., Tumanian G.S., Koziakov A.E., Gil'mutdinova L.A., Osipov M.A., Shatokhina A.S., Vazhenina A.A., Chichkanova A.S., Vladimirov V.I., Ivanov A.N., Belokhvostova A.S., Cherniakova E.M., Tul'china E.A., Maklashova S.A., Shkodenko O.N., Kostalanova I.V., Tarasova A.V., Kuz'mina E.S. |
| Vol 19, No 4 (2017) |
Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0 |
|
|
Pavlikova O.A., Poddubnaya I.V., Kolyadina I.V., Abdullaev A.G., Komov D.V., Danzanova T.Y., Sinyukova G.T., Kozlov N.A., Ganshina I.P., Zhukova L.G., Aliyeva G.S., Kerimov R.A., Gordeeva O.O. |
| Vol 18, No 4 (2016) |
Fulvestrant in endocrine therapy of recurrent and metastatic breast cancer |
|
|
Vladimirova L.Y. |
| Vol 17, No 2 (2015) |
Brain metastases in her2-positive breast cancer: new opportunities for systemic therapy |
|
|
Artamonova E.V., Manziuk L.V. |
| Vol 16, No 2 (2014) |
High efficiency of lapatinib in combination with capecitabine in patient with metastatic HER2-positive synchronous breast cancer (case study) |
|
|
Seryakov A.P., Ovchinnikova L.K., Zabelin M.V., Yakubov T.Z., Sidorov D.B., Ovchinnikov M.V. |
| Vol 15, No 2 (2013) |
New possibilities of chemotherapy for anthracyclineand/or taxane-resistant breast cancer |
|
|
Artamonova E.V., Manzyuk L.V. |
| Vol 7, No 2 (2005) |
Biologicheskie kharakteristiki opukholi (proliferativnaya aktivnost', ploidnost' i steroidnye retseptory) i ikh vliyanie na neposredstvennye i otdalennye rezul'taty lecheniya zapushchennogo raka molochnoy zhelezy |
|
|
Nikolaeva T.G., Vyshinskaya G.V., Rotobel'skaya L.E. |
| Vol 10, No 1 (2008) |
Effektivnost' ad\"yuvantnoy terapii anastrozolom i tamoksifenom u patsientok s rannimi stadiyami raka molochnoy zhelezy (analiz dannykh issledovaniya ATAC pri mediane vremeni nablyudeniya 100 mes) |
|
| Vol 20, No 1 (2018) |
Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin |
|
|
Kolbin A.S., Mosikyan A.A., Balykina Y.E., Proskurin M.A. |
| Vol 15, No 3 (2013) |
Rezul'taty «Epidemiologicheskoy programmy skrininga HER2-statusa u bol'nykh rakom molochnoy zhelezy» v Rossiyskoy Federatsii |
|
|
Frank G.A., Poddubnaya I.V., Yagudina R.I., Borisov D.A. |
| Vol 21, No 2 (2019) |
The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience |
|
|
Kolyadina I.V., Bulavina I.S., Petkau V.V., Strakhova N.V., Gorbunova V.A., Kovalenko E.I., Manziuk L.V., Artamonova E.V., Zhukova L.G., Bolotina L.V., Gan'shina I.P., Semiglazova T.I., Manikhas A.G., Raevskaia N.A., Itkin I.M., Khokhlova S.V., Filonenko D.V., Gol'dberg V.E., Popova N.O., Ponomarenko D.M., Shikina V.E., Vladimirova L.I., Tikhanovskaia N.M., Karabina E.V., Mukhametshina G.Z., Khasanova A.I., Safina S.Z., Shaidorov M.V., Orlov A.E., Kostalanova I.V., Levchenko N.V., Osipov M.A., Karandeeva T.V., Evstigneeva I.V., Chernov I.S., Kolokolov D.D., Povyshev A.I., Shatokhina A.S., Cherniakova E.M., Shkodenko O.N., Kuz'mina E.S. |
| Vol 17, No 2 (2015) |
The role and assessment of morphological regression after neoadjuvant therapy in breast cancer patients |
|
|
Frank G.A., Ilatovskaia M.E., Andreeva I.I., Zavalishina L.E. |
| Vol 16, No 3 (2014) |
Modern treatment possibilities of hormone receptor-positive advanced breast cancer in postmenopausal women |
|
|
Jackisch C., Llombart-Cussac A. |
| Vol 16, No 1 (2014) |
New chemotherapy options for triple-negative breast cancer (review of literature) |
|
|
Sekundova M.A., Zdvizhkov A.M., Borisov V.I. |
| Vol 18, No 3 (2016) |
Circulating tumor cell: biology, methods of isolation, clinical significance in breast cancer |
|
|
Nenahova Y.N., Lyadov V.K., Poddubnaya I.V. |
| Vol 11, No 2 (2009) |
Kachestvo zhizni i simptomyu bol'nykh disseminirovannym gormonopozitivnym rakom molochnoy zhelezy v postmenopauze na fone primeneniya Fazlodeksa |
|
|
Novik A.A., Ionova T.I., Kalyadina S.A. |
| Vol 9, No 3 (2007) |
Femara (letrozol) v ad\"yuvantnoy terapii raka molochnoy zhelezy |
|
|
Stenina M.B. |
| Vol 16, No 2 (2014) |
The results of Epidemiological HER2 screening program in patients with breast cancer in 2013 |
|
|
Frank G.A., Poddubnaya I.V., Yagudina R.I., Borisov D.A., Koroleva N.I. |
| Vol 11, No 3 (2009) |
Klinicheskaya effektivnost'i bezopasnost' primeneniya otechestvennogo rekombinantnogo granulotsitarnogo koloniestimuliruyushchego faktora Neypomaks® u bol'nykh rakom molochnoy zhelezy, poluchayushchikh khimioterapiyu doksorubitsinom i dotsetakselom |
|
|
Zhukova L.G., Abramov M.E., Vakhabova Y.V., Lud A.N., Obukhov A.A., Lichinitser M.R. |
| Vol 10, No 1 (2008) |
Tayverb/Tyverb (lapatinib) – pervyy dvoynoy anti-ErbB1(EGFR)i anti-ErbB2(HER2)-ingibitor v lechenii mestno-rasprostranennogo i metastaticheskogo raka molochnoy zhelezy zaregistrirovan v Rossiyskoy Federatsii |
|
| Vol 21, No 3 (2019) |
Immunotherapy in combination with chemotherapy in triple-negative breast cancer - the first “target” therapy for the “target” patients’ population |
|
|
Grechukhina K.S., Zhukova L.G. |
| Vol 11, No 2 (2009) |
HER-2-targetnaya terapiya raka molochnoy zhelezy: monoklonal'nye antitela i ingibitory tirozinkinazy |
|
|
Ognerubova I.N. |
| Vol 9, No 2 (2007) |
Ad\"yuvantnaya endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy |
|
|
Semiglazov V.F., Semiglazov V.V. |
| Vol 18, No 2 (2016) |
Cost-effectiveness of empegfilgrastim (Extimia®) for the prevention of severe neutropenia in patients with malignant neoplasm of female breast |
|
|
Rudakova A.V., Tolkacheva D.G., Gavrilova O.N., Vaganov A.S. |
| Vol 16, No 2 (2014) |
Difficulties in treating patients with breast cancer in Russia: the resolution on the results of the Review Board |
|
|
Artamonova E.V., Gorbunova V.A., Zhukov N.V., Manzjuk L.V., Manihas A.G., Paltuev P.M., Semiglazov V.F., Semiglazova T.Y., Stenina M.B., Tjuljandin S.A., Chubenko V.A. |
| Vol 7, No 2 (2005) |
«Problema optimizatsii ad\"yuvantnoy endokrinnoy terapii na rannikh stadiyakh raka molochnoy zhelezy» |
|
|
Semiglazov V.F., Poddubnaya I.V. |
| Vol 11, No 3 (2009) |
Klinicheskiy sluchay effektivnogo lecheniya lapatinibom (Tayverb)i kapetsitabinom (Kseloda) bol'noy disseminirovannym rakom molochnoy zhelezy s giperekspressiey ErbB2 (Her-2/neu) s metastaticheskim porazheniem veshchestva i obolochek golovnogo mozga |
|
|
Naskhletashvili D.R., Chmutin G.E. |
| Vol 10, No 1 (2008) |
8 let nadezhdy: novye dannye issledovaniya ATAS |
|
| Vol 20, No 1 (2018) |
Dermatomyositis and polymyositis in breast cancer patients: a case reports |
|
|
Ganshina I.P., Zhukova L.G., Burnevitch E.Z., Gordeeva O.O., Kondratieva O.E. |
| Vol 17, No 3 (2015) |
The results of Epidemiological HER2 screening program in patients with breast cancer in 2014 |
|
|
Poddubnaya I.V., Frank G.A., Yagudina R.I., Koroleva N.I., Zavalishina L.E. |
| Vol 11, No 2 (2009) |
Rol' Taksotera v lechenii metastaticheskogo raka molochnoy zhelezy |
|
|
Kolyadina I.V., Makarenko N.P., Poddubnaya I.V. |
| Vol 19, No 3 (2017) |
Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving |
|
|
Artamonova E.V. |
| Vol 18, No 3 (2016) |
The role of nab-paclitaxel in the treatment of patients with metastatic breast cancer |
|
|
Frolova M.A. |
| Vol 7, No 1 (2005) |
Opyt primeneniya Regional'noy programmy v g. Krasnodare |
|
|
Mitashok I.S. |
| Vol 15, No 4 (2013) |
Bone mineral density in patient with breast cancer |
|
|
Poddubnaya I.V., Kizhaev E.V., Kolyadina I.V., Banov S.M., Zhmaeva E.M., Secko M.A. |
| Vol 11, No 3 (2009) |
Predoperatsionnaya (neoad\"yuvantnaya) endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy |
|
|
Semiglazov V.F., Semiglazov V.V., Zhil'tsova E.K. |
| Vol 11, No 2 (2009) |
Sravnitel'noe issledovanie opredeleniya HER2-statusa raka molochnoy zhelezy metodami immunogistokhimii i in situ gibridizatsii |
|
|
Zavalishina L.E., Andreeva Y.Y., Ryazantseva A.A., Bateva M.V., Frank G.A. |
| Vol 9, No 2 (2007) |
Sovremennaya taktika ad\"yuvantnoy lekarstvennoy terapii bol'nykh operabel'nym (rannim) rakom molochnoy zhelezy |
|
|
Perevodchikova N.I. |
| Vol 18, No 2 (2016) |
Bioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients: findings of the international, double-blind phase III clinical study |
|
|
Ignatova E.O., Burdaeva O.N., Kopp M.V., Kotiv B.N., Udovitsa D.P., Stroiakovskii D.L., Alekseev S.M., Sheveleva L.P., Khorinko A.V., Shapovalova I.S., Moiseenko V.M., Ivanov R.A. |
| Vol 17, No 1 (2015) |
Radiation-induced lung injury in breast cancer patients after breast conservation therapy |
|
|
Trofimova O.P., Tkachev S.I., Ivanov S.M., Utkina V.L., Cheban O.I., Glebovskaya V.V. |
| Vol 16, No 2 (2014) |
Press-release. «Sanofi» makes a contribution in improving availability of treatment in women with breast cancer in Russia in accordance with international standards |
|
| Vol 15, No 1 (2013) |
Current approach to adjuvant therapy for breast cancer (a review) |
|
|
Conte P., Guarneri V. |
| Vol 7, No 1 (2005) |
Analiz rezul'tatov vnedreniya Regional'noy rossiyskoy programmy lecheniya pervichno-generalizovannogo i metastaticheskogo raka molochnoy zhelezy v Voronezhskom oblastnom klinicheskom onkologicheskom dispansere |
|
|
Chevardov N.I., Tolstykh L.V., Puzakov K.G., Potapov Y.N. |
| 1 - 100 of 106 Items |
1 2 > >> |
